Year: 2005
Type: article
Abstract: Selective serotonin reuptake inhibitors (SSRIs) can safely and successfully treat major depression, although a substantial number of patients benefit only partially or not at all from treatment. Genetic polymorphisms may play a major role in determining the response to SSRI treatment. Nonetheless, it is likely that efficacy is determined by multiple genes, with individual genetic polymorphisms having a limited effect size. Initial studies have identified the promoter polymorphism in the gene coding for the serotonin reuptake transporter as moderating efficacy for several SSRIs. The goal of this review is to suggest additional plausible polymorphisms that may be involved in antidepressant efficacy. These include genes affecting intracellular transductional cascades; neuronal growth factors; stress-related hormones, such as corticotropin-releasing hormone and glucocorticoid receptors; ion channels and synaptic efficacy; and adaptations of monoaminergic pathways. Association analyses to examine these candidate genes may facilitate identification of patients for targeted alternative therapies. Determining which genes are involved may also assist in identifying future, novel treatments.
Authors: Francis E Lotrich, Bruce G Pollock
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: selective serotonin reuptake inhibitors, antidepressant response, major depressive disorder, genetic polymorphism, candidate genes, serotonin transporter, promoter polymorphism, intracellular signaling cascades, neuronal growth factors, corticotropin-releasing factor, glucocorticoid receptor, ion channels, synaptic efficacy, monoaminergic pathways, pharmacogenetics, treatment-resistant depression
Open Access status: green
OpenAlex ID: W1964888885
